Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM8RD4T)

• Drug Name: EC0489 Drug Info
• Synonyms: EC-0489

Indication

Disease Entry	ICD 11	Status	REF
Solid tumour/cancer	2A00-2F9Z	Phase 1	[1]

• Cross-matching ID:
  PubChem CID: 25229525
  TTD Drug ID: DM8RD4T

Molecule-Related Drug Atlas

Drug(s) Targeting Folate receptor alpha (FOLR1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Pyrimethamine	DM5X7VY	Malaria	1F40-1F45	Approved	[3]
Mirvetuximab soravtansine	DM5S4LX	Ovarian cancer	2C73	Approved	[4]
EC20	DMLA1ER	Ovarian cancer	2C73	Phase 3	[5]
MK-8109	DM84LO5	Ovarian cancer	2C73	Phase 3	[6]
Farletuzumab	DMFLWX1	Non-small-cell lung cancer	2C25.Y	Phase 3	[7]
EC-145	DM0KVJC	Solid tumour/cancer	2A00-2F9Z	Phase 2	[8]
FolateImmune	DMB9ADM	Renal cell carcinoma	2C90	Phase 2	[9]
Talotrexin	DM1AB4L	Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[10]
BMS-753493	DMDQO0S	Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[11]
IMGN-853	DMR8OG2	Solid tumour/cancer	2A00-2F9Z	Phase 1	[12]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Folate receptor alpha (FOLR1)	TTVC37M	FOLR1_HUMAN	Modulator	[2]

References

• [1] ClinicalTrials.gov (NCT00852189) Study of EC0489 for the Treatment of Refractory or Metastatic Tumors. U.S. National Institutes of Health.
• [2] National Cancer Institute Drug Dictionary (drug id 638649).
• [3] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [4] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [5] EP patent application no. 2822386, Folate receptor alpha binding ligands.
• [6] A current review of folate receptor alpha as a potential tumor target in non-small-cell lung cancer. Drug Des Devel Ther. 2015; 9: 4989-4996.
• [7] Farletuzumab (a monoclonal antibody against folate receptor alpha) in relapsed platinum-sensitive ovarian cancer.Gynecol Oncol.2013 Jun;129(3):452-8.
• [8] Significance of Folate Receptor alpha and Thymidylate Synthase Protein Expression in Patients with Non-Small Cell Lung Cancer treated with Pemetrexed. J Thorac Oncol. 2013 January; 8(1): 19-30.
• [9] Responsiveness of the Effective Consumer Scale (EC-17). J Rheumatol. 2009 Sep;36(9):2087-91.
• [10] Cancer chemotherapy: targeting folic acid synthesis. Cancer Manag Res. 2010; 2: 293-301.
• [11] A phase I pharmacokinetic and safety analysis of epothilone folate (BMS-753493), a folate receptor targeted chemotherapeutic agent in humans with advanced solid tumors. Invest New Drugs. 2015 Apr;33(2):321-31.
• [12] Tumor delivery and in vivo processing of disulfide-linked and thioether-linked antibody-maytansinoid conjugates. Bioconjug Chem. 2010 Jan;21(1):84-92.